Aura Biosciences appoints new CEO as Phase 3 trial for eye cancer treatment nears enrollment completion

Aura Biosciences has appointed Natalie Holles as CEO, succeeding founder Elisabet de los Pinos, as the company advances its Phase 3 CoMpass trial for belzupacap sarotalocan (bel-sar), a treatment for early choroidal melanoma. The trial is nearing enrollment completion with 86 patients enrolled and more scheduled, aiming to finish by mid-2026 with topline data expected in late 2027. Bel-sar has potential as the first frontline, vision-preserving therapy for this rare eye cancer. Holles brings extensive experience in rare disease commercialization, positioning Aura for growth and potential market launch.